财中社11月28日电先声药业（02096）发布公告，宣布其三款创新药物科赛拉®、恩立妥®和先必新®已成功纳入新版国家医保药品目录。该公告于2024年11月28日发布，标志着公司在国家医保谈判中取得了重要进展。其中，科赛拉®和恩立妥®为此次谈判新增产品，而先必新®则为续约产品。
科赛拉®是一种新型CDK4/6抑制剂，具备全系骨髓保护作用；恩立妥®为重组抗EGFR单克隆抗体，已于2024年6月18日获得上市批准，适用于转移性结直肠癌的治疗。先必新®自2020年12月纳入医保，并于2023年1月成功续约。公司致力于创新与研发，聚焦神经科学、抗肿瘤、自身免疫及抗感染领域，推动药物的临床应用。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.